Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 3.22 kCr |
| Price/Earnings (Trailing) | 21.12 |
| Price/Sales (Trailing) | 4.31 |
| EV/EBITDA | 12.26 |
| Price/Free Cashflow | 31.91 |
| MarketCap/EBT | 14.88 |
| Enterprise Value | 3.17 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | -3.2% |
| Price Change 1M | -8% |
| Price Change 6M | -5.6% |
| Price Change 1Y | -16.4% |
| 3Y Cumulative Return | 0.90% |
| 5Y Cumulative Return | -3% |
| 7Y Cumulative Return | 8.2% |
Cash Flow & Liquidity |
|---|
| Revenue (TTM) |
| 745.92 Cr |
| Rev. Growth (Yr) | 2% |
| Earnings (TTM) | 155.08 Cr |
| Earnings Growth (Yr) | 11.1% |
Profitability | |
|---|---|
| Operating Margin | 28% |
| EBT Margin | 28% |
| Return on Equity | 9.83% |
| Return on Assets | 8.91% |
| Free Cashflow Yield | 3.13% |
| Cash Flow from Investing (TTM) | -89.1 Cr |
| Cash Flow from Operations (TTM) | 142.5 Cr |
| Cash Flow from Financing (TTM) | -72.54 Cr |
| Cash & Equivalents | 62.36 Cr |
| Free Cash Flow (TTM) | 108.69 Cr |
| Free Cash Flow/Share (TTM) | 9.71 |
Balance Sheet | |
|---|---|
| Total Assets | 1.69 kCr |
| Total Liabilities | 158.33 Cr |
| Shareholder Equity | 1.53 kCr |
| Current Assets | 933.46 Cr |
| Current Liabilities | 106.73 Cr |
| Net PPE | 284.45 Cr |
| Inventory | 173.42 Cr |
| Goodwill | 348.09 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.01 |
| Debt/Equity | 0.01 |
| Interest Coverage | 64.1 |
| Interest/Cashflow Ops | 42.34 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 5.2 |
| Dividend Yield | 1.81% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.10% |
Growth: Good revenue growth. With 35.3% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 20%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Past Returns: Underperforming stock! In past three years, the stock has provided 0.9% return compared to 13.2% by NIFTY 50.
Momentum: Stock is suffering a negative price momentum. Stock is down -8% in last 30 days.
Growth: Good revenue growth. With 35.3% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 20%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Past Returns: Underperforming stock! In past three years, the stock has provided 0.9% return compared to 13.2% by NIFTY 50.
Momentum: Stock is suffering a negative price momentum. Stock is down -8% in last 30 days.
Investor Care | |
|---|---|
| Dividend Yield | 1.81% |
| Dividend/Share (TTM) | 5.2 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 13.61 |
Financial Health | |
|---|---|
| Current Ratio | 8.75 |
| Debt/Equity | 0.01 |
Technical Indicators | |
|---|---|
| RSI (14d) | 55.13 |
| RSI (5d) | 42.39 |
| RSI (21d) | 42.07 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of Advanced Enzyme Tech's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management's outlook for Advanced Enzyme Technologies remains cautiously optimistic despite global market disruptions. Key highlights from the call include:
Revenue Growth: The company reported a quarter revenue of INR 1,719 million, marking a 2% year-over-year increase but a 7% decline from the previous quarter. Year-to-date revenue has grown by 15% to INR 5,424 million.
EBITDA Performance: EBITDA stood at INR 494 million for the quarter, reflecting an 11% decrease year-over-year and an 18% decline from the prior quarter, while it increased 11% year-to-date. The EBITDA margin for Q3 was 29%, down from 33% in the same quarter last year.
Profit After Tax (PAT): The PAT increased to INR 432 million, reflecting an 11% growth year-over-year, but a 3% decline quarter-over-quarter. The PAT margin was 25% for the quarter and 24% year-to-date.
Segment Performance:
Global Market Dynamics: The management highlighted the reduction of reciprocal tariffs from 25% to 18% and the removal of a penal levy, which could enhance competitiveness in the U.S. market.
Future Strategy: Management is focused on enhancing operational resilience to adapt to changing market conditions and strives for continuous growth across segments. They anticipate a robust growth trajectory, leveraging advancements in R&D.
Overall, while the past performance has been mixed, management is committed to navigating upcoming challenges and capitalizing on opportunities for growth across sectors, confident in achieving a long-term growth rate of 13-15%.
Understand Advanced Enzyme Tech ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Vasant Rathi | 26.47% |
| Orbimed Asia III Mauritius FVCI Limited | 12.07% |
| Nalanda India Equity Fund Limited | 8.46% |
| Vasant and Prabha Rathi Generation Trust | 6.7% |
| Clarus Capital I | 2.65% |
| Rasika Vasant Rathi | 2.38% |
| Rachana Vasant Rathi | 2.36% |
Detailed comparison of Advanced Enzyme Tech against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| BIOCON | Biocon | 48.85 kCr | 16.72 kCr | -5.60% | -8.00% | 91.12 | 2.92 | - | - |
| SEQUENT | Sequent Scientific | 8.79 kCr | 2.15 kCr |
Comprehensive comparison against sector averages
ADVENZYMES metrics compared to Pharmaceuticals
| Category | ADVENZYMES | Pharmaceuticals |
|---|---|---|
| PE | 21.12 | 33.51 |
| PS | 4.31 | 4.65 |
| Growth | 12.8 % | 9.1 % |
Advanced Enzyme Technologies Limited, commonly known as Advanced Enzyme Tech, is a biotechnology company based in Thane, India. The company operates under the stock ticker ADVENZYMES and boasts a market capitalization of Rs. 3,225 Crores.
The core focus of Advanced Enzyme Tech is on the research, development, manufacture, and marketing of enzymes and probiotics across various sectors. Their offerings cater to both human healthcare and animal nutrition, with applications in:
In addition to these, Advanced Enzyme Tech also develops non-food processing enzymes for industries such as textiles, leather, pulp and paper, detergents, and cleaning aids.
Founded in 1957 and formerly known as Advanced Biochemicals Limited until its name change in 2005, Advanced Enzyme Tech has shown significant financial growth. The company reported a trailing 12-month revenue of Rs. 661.3 Crores and a profit of Rs. 137.1 Crores over the previous four quarters. It has experienced revenue growth of 23.5% over the past three years and distributes dividends to its investors, with a dividend yield of 1.79% and a payout of Rs. 6.1 per share in the last year.
However, it is noteworthy that the company has diluted its shareholders' stakes slightly by 0.1% in the past three years.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
ADVENZYMES vs Pharmaceuticals (2021 - 2026)
1. Question from Umang Shah: "Could you break down the human nutrition revenue between India and international?"
Answer: For the nine months, India's revenue stood at INR 1,710 million, while international revenue was INR 1,686 million, totaling INR 3,396 million.
2. Question from Umang Shah: "What led to the decline in the human nutrition segment, especially in the U.S. nutraceutical business?"
Answer: The market in the U.S. is highly uncertain, affecting overall consumer behavior. Rising costs for raw materials have hampered order placements, as everyone in the nutrition market is experiencing similar pressures.
3. Question from Sajal Kapoor: "How are you monitoring disruptive technologies in the enzyme space?"
Answer: We continuously research and publish papers to maintain our competitive edge. Our focus on producing data-supported ingredients ensures we stay relevant while navigating regulatory approvals.
4. Question from Rohan: "What is your outlook for U.S. sales going ahead, especially after recent tariff reductions?"
Answer: While the tariff reduction to 18% is beneficial, price competitiveness remains crucial. We foresee an improved outlook, contingent on the broader economic conditions and customer comfort with pricing strategies.
5. Question from Abhishek Navalgund: "What area will your upcoming R&D center focus on?"
Answer: The new R&D center in Nashik will primarily focus on strain development, protein engineering, and fermentation processes, aiming to foster innovation for future revenue-generating products.
6. Question from Ketan Chheda: "Why have revenues in the EU region not grown significantly despite multiple product approvals?"
Answer: Our primary focus in Europe has been on the food segment, and while we secured approvals, sales growth has been slower due to market dynamics and is not solely reliant on product registration.
7. Question from Ravi Purohit: "What specific growth areas outside the U.S. do you see contributing to sustained growth?"
Answer: Significant results are coming from registrations and expansions in Asia and other global markets, which we anticipate will contribute to sustainable growth over the coming years.
8. Question from Rohan: "What are the margin impacts expected from recent tariffs?"
Answer: Instead of a 200 bps impact, the revised outlook indicates about a 100 bps effect on EBITDA margins based on current tariff conditions and our cost-pass-through strategies.
This Q&A section reflects the major concerns from analysts and investors, highlighting both the challenges and growth opportunities that Advanced Enzyme Technologies is navigating.
| Reshma Namita Rathi | 2.36% |
| Marval Guru Fund | 1.79% |
| Pradip Bhailal Shah | 1.68% |
| Mukund Madhusudan Kabra | 1.63% |
| Polunin Emerging Markets Small Cap Fund, LLC | 1.38% |
| Kishor Laxminarayan Rathi HUF | 0.98% |
| Prabhavati Vasant Rathi | 0.82% |
| Madhusudan Kabra | 0.55% |
| Kishor Laxminarayan Rathi | 0.36% |
| Megha Jhawar | 0.01% |
| Jayesh Madhusudan Soni | 0.01% |
| Shruti Sharad Dhamdhere | 0.01% |
| Pratik Prakash Kokane | 0.01% |
Distribution across major stakeholders
Distribution across major institutional holders
| -3.60% |
| +23.60% |
| 83.29 |
| 4.09 |
| - |
| - |
| NEOGEN | Neogen Chemicals | 3.57 kCr | 804.36 Cr | +19.30% | -36.00% | 136.99 | 4.44 | - | - |
| AARTIDRUGS | Aarti Drugs | 3.42 kCr | 2.53 kCr | -7.30% | -11.70% | 16.89 | 1.35 | - | - |
| ROSSARI | ROSSARI BIOTECH | 2.88 kCr | 2.3 kCr | -9.00% | -29.40% | 20.87 | 1.25 | - | - |
| 135 |
| 140 |
| 132 |
| 124 |
| 114 |
| Profit Before exceptional items and Tax | -22% | 47 | 60 | 55 | 43 | 53 | 42 |
| Exceptional items before tax | - | 11 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | -3.4% | 58 | 60 | 55 | 43 | 53 | 42 |
| Current tax | -26.7% | 12 | 16 | 15 | 14 | 14 | 8.68 |
| Deferred tax | 215.4% | 3.17 | -0.88 | -1.01 | 2.58 | 0.32 | 0.13 |
| Total tax | 0% | 15 | 15 | 14 | 17 | 14 | 8.82 |
| Total profit (loss) for period | -4.5% | 43 | 45 | 40 | 27 | 39 | 33 |
| Other comp. income net of taxes | -63.3% | 12 | 31 | 3.77 | 0.66 | 13 | 4.9 |
| Total Comprehensive Income | -28% | 55 | 76 | 44 | 27 | 52 | 38 |
| Earnings Per Share, Basic | -2.4% | 3.8 | 3.87 | 3.57 | 2.37 | 3.36 | 2.94 |
| Earnings Per Share, Diluted | -2.8% | 3.79 | 3.87 | 3.57 | 2.37 | 3.36 | 2.93 |
| Debt equity ratio | 0% | 001 | 001 | 002 | 002 | - | 0 |
| Debt service coverage ratio | 1.2% | 0.0968 | 0.0862 | 0.0696 | 0.0554 | - | - |
| Interest service coverage ratio | -2.7% | 0.6791 | 0.6874 | 0.6065 | 0.4143 | - | - |
| 0.24 |
| 0.16 |
| 0.14 |
| 0.1 |
| 0.08 |
| 1.1 |
| Depreciation and Amortization | 0% | 11 | 11 | 10 | 9.56 | 8.93 | 8.81 |
| Other expenses | 3.8% | 82 | 79 | 72 | 62 | 52 | 49 |
| Total Expenses | 7.8% | 292 | 271 | 247 | 210 | 192 | 180 |
| Profit Before exceptional items and Tax | -21.1% | 121 | 153 | 74 | 72 | 98 | 76 |
| Exceptional items before tax | 95% | 0 | -18.95 | 0 | 0 | 0 | 0 |
| Total profit before tax | -9.8% | 121 | 134 | 74 | 72 | 98 | 76 |
| Current tax | -38.5% | 17 | 27 | 18 | 18 | 25 | 19 |
| Deferred tax | 110.6% | 1.22 | -1.08 | 0.5 | -0.46 | 2.57 | -1.49 |
| Total tax | -32% | 18 | 26 | 19 | 18 | 27 | 18 |
| Total profit (loss) for period | -5.6% | 102 | 108 | 56 | 55 | 71 | 58 |
| Other comp. income net of taxes | -21.8% | -0.34 | -0.1 | 0.49 | 0.02 | -0.03 | -0.32 |
| Total Comprehensive Income | -5.6% | 102 | 108 | 56 | 55 | 71 | 58 |
| Earnings Per Share, Basic | -5.9% | 9.16 | 9.67 | 4.97 | 4.88 | 6.36 | 5.19 |
| Earnings Per Share, Diluted | -5.9% | 9.15 | 9.66 | 4.97 | 4.87 | 6.35 | 5.18 |
| Debt equity ratio | - | - | 0 | - | 0 | 0 | 002 |
| Debt service coverage ratio | - | - | - | - | - | - | 011 |
| 50% |
| 31 |
| 21 |
| 21 |
| 16 |
| 9.25 |
| 5.61 |
| Non-current investments | 0% | 254 | 254 | 206 | 205 | 218 | 185 |
| Loans, non-current | -5.3% | 0.01 | 0.06 | 0 | 0.04 | 0.51 | 33 |
| Total non-current financial assets | -7.9% | 257 | 279 | 208 | 208 | 221 | 221 |
| Total non-current assets | 1.1% | 461 | 456 | 404 | 385 | 397 | 387 |
| Total assets | 8.7% | 749 | 689 | 666 | 633 | 619 | 576 |
| Borrowings, non-current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial liabilities | -203.1% | 0 | 1.97 | 2.46 | 0 | 1.27 | 1.45 |
| Provisions, non-current | 227.8% | 1.23 | 0.82 | 0.66 | 0.66 | 0.32 | 0.32 |
| Total non-current liabilities | 0% | 15 | 15 | 14 | 12 | 13 | 14 |
| Borrowings, current | - | 0 | 0 | 0 | 0 | 0 | 0.01 |
| Total current financial liabilities | 44.4% | 53 | 37 | 39 | 34 | 46 | 31 |
| Provisions, current | -31.1% | 2.75 | 3.54 | 1.64 | 2.54 | 1.62 | 1.99 |
| Current tax liabilities | 0% | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
| Total current liabilities | 43.2% | 64 | 45 | 49 | 40 | 50 | 37 |
| Total liabilities | 32.8% | 78 | 59 | 63 | 52 | 63 | 50 |
| Equity share capital | 0% | 22 | 22 | 22 | 22 | 22 | 22 |
| Total equity | 6.7% | 671 | 629 | 602 | 580 | 556 | 525 |
| Total equity and liabilities | 8.7% | 749 | 689 | 666 | 633 | 619 | 576 |
| -0.5% |
| -1.13 |
| -1.12 |
| -3.4 |
| 0.04 |
| - |
| - |
| Income taxes paid (refund) | -19.2% | 22 | 27 | 16 | 21 | - | - |
| Net Cashflows From Operating Activities | 12.7% | 63 | 56 | 50 | 37 | - | - |
| Proceeds from sales of PPE | 95.4% | 0 | -20.61 | 0.15 | 0 | - | - |
| Purchase of property, plant and equipment | - | 22 | 0 | 23 | 11 | - | - |
| Proceeds from sales of investment property | -1.1% | 0.12 | 0.13 | 0 | 1.24 | - | - |
| Purchase of investment property | - | 0 | 0 | 0 | 21 | - | - |
| Proceeds from sales of intangible assets | - | 0 | 0 | 0 | 16 | - | - |
| Purchase of intangible assets | 5.2% | 0.08 | 0.03 | 0.05 | 0.06 | - | - |
| Dividends received | 5.8% | 56 | 53 | 3.16 | 3.82 | - | - |
| Interest received | 225% | 1.39 | 1.12 | 0.19 | 0 | - | - |
| Other inflows (outflows) of cash | 7.8% | -36.94 | -40.17 | -22.38 | -3.93 | - | - |
| Net Cashflows From Investing Activities | 65.2% | -1.74 | -6.88 | -42.35 | -14.28 | - | - |
| Proceeds from issuing shares | - | 0.38 | 0 | 0.14 | 0.43 | - | - |
| Repayments of borrowings | -1% | 0 | 0.01 | 0 | 0.72 | - | - |
| Payments of lease liabilities | 90% | 0.98 | 0.8 | 0.65 | 0.43 | - | - |
| Dividends paid | 1.8% | 57 | 56 | 11 | 10 | - | - |
| Interest paid | -19% | 0 | 0.16 | 0.14 | 0.09 | - | - |
| Other inflows (outflows) of cash | - | 0 | 0 | -0.17 | 0 | - | - |
| Net Cashflows from Financing Activities | -1.3% | -57.63 | -56.88 | -11.99 | -10.87 | - | - |
| Net change in cash and cash eq. | 134.7% | 4.11 | -7.95 | -4.05 | 12 | - | - |